Patent classifications
A61K51/047
Cholecystokinin B receptor targeting for imaging and therapy
Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.
Radiolabeled and fluorescent PARP inhibitors for imaging and radiotherapy
The present disclosure relates to compounds of Formula I and II, wherein R.sup.1-R.sup.20 and FL are defined herein. Also provided are methods of targeting alpha-radiation to poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, reducing proliferation of cancer cells, reducing proliferation of cancer cells, detecting intact and enzymatically active poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, detecting PARP-1 enzyme expression in a subjects tissue sample, monitoring cancer treatment in a subject, or detecting a PARP-1 receptive cancer in a subject. ##STR00001##
CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY
Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.
NOVEL COMPOUND BINDING TO DESIGNER RECEPTOR, IMAGING METHOD FOR DESIGNER RECEPTOR, AGONIST OR ANTAGONIST, THERAPEUTIC AGENT, COMPANION DIAGNOSTIC AGENT, AND IMAGING METHOD FOR NERVE CELL
The purpose of the present invention is to provide a technique for imaging the brain of a live animal and application of the technique. A radiolabeled dibenzoazepine derivative, which shows excellent brain parmeability, high receptor selectivity and high quantitativity, is used for imaging a live animal body. A dibenzoazepine derivative is used for treating a disease in which hM4D receptor or hM3D receptor participates. Further, a radiolabeled dibenzoazepine derivative is used for imaging an axonal end which is innervated by a nerve cell.
CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY
Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.
RADIOLABELED AND FLUORESCENT PARP INHIBITORS FOR IMAGING AND RADIOTHERAPY
The present disclosure relates to compounds of Formula I and II, wherein R.sup.1-R.sup.20 and FL are defined herein. Also provided are methods of targeting alpha-radiation to poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, reducing proliferation of cancer cells, reducing proliferation of cancer cells, detecting intact and enzymatically active poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, detecting PARP-1 enzyme expression in a subjects tissue sample, monitoring cancer treatment in a subject, or detecting a PARP-1 receptive cancer in a subject.
##STR00001##
CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY
Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.
PET IMAGING TRACERS
18-Fluoride is an ideal positron emitting radioisotope for imaging with peptides and peptide-like molecules due to the complementary biological half-like of peptides matched to the decay half-life of 18-fluoride (109 minutes). Disclosed herein, inter alia, are PET imaging tracer compounds and methods of use thereof.
Precursor compound connected to solid support for manufacturing 18F radiopharmaceutical, method for manufacturing same, and application thereof
The present invention relates to a solid precursor in the form of an organic salt, the solid precursor having a solid support, a method for manufacturing same, and an application thereof. The solid precursor of the present invention enables omission of the [.sup.18F]fluoride refining process using additional cartridge, and the use of excessive phase-transfer catalyst, and can easily remove remaining substance after reaction through the solid support inside the precursor. The solid precursor of the present invention is very appropriate for an automated synthesis device as an all-in-one system that can carry out overall process of [.sup.18F]fluorosis reaction, when used by charging in a cartridge.
IMAGING METHOD FOR DESIGNER RECEPTOR, ANTAGONIST OR AGONIST, PHARMACEUTICAL, AND COMPANION DIAGNOSTIC AGENT
The purpose of the present invention is to provide a technique for imaging the brain of a live animal and application of the technique. A radiolabeled dibenzoazepine derivative, which shows excellent brainparmeability, high receptor selectivity and high quantitativity, is used for imaging a live animal body. A dibenzoazepine derivative is used for treating a disease in which hM4D receptor or hM3D receptor participates. Further, a radiolabeled dibenzoazepine derivative is used for imaging an axonal end which is innervated by a nerve cell.